This bill replaces and expands Section 804 of the Federal Food, Drug, and Cosmetic Act to create a regulated pathway for importing certain prescription drugs from Canada, the United Kingdom, EU member states, Switzerland, and potentially additional countries. It requires the Secretary of Health and Human Services to issue implementing regulations within one year and builds a certification regime for foreign pharmacies and wholesale distributors, a public list of certified sellers, random laboratory testing, labeling rules, and an information‑reporting system for U.S. importers.
The measure aims to reduce out‑of‑pocket spending by allowing individuals to import limited personal supplies and enabling licensed U.S. wholesalers and pharmacies to import qualifying products. At the same time it imposes new compliance obligations — certification fees, biannual reporting, traceability requirements, and suspension authority — and creates criminal penalties for internet actors who intentionally sell adulterated or counterfeit drugs to U.S. consumers.
At a Glance
What It Does
Rewrites the importation provision in the FD&C Act to permit specified cross‑border imports of 'qualifying prescription drugs' under an FDA certification and oversight program. It defines qualifying drugs, establishes criteria and fees for 'certified foreign sellers,' authorizes laboratory testing and suspension of noncompliant imports, and preserves FDA authority over REMS‑subject products.
Who It Affects
Directly affects U.S. dispensers and wholesale distributors that register as importers, licensed foreign pharmacies and foreign wholesale distributors seeking certification, prescription drug manufacturers, and patients who pay cash or face high cost‑sharing. It also pulls the FDA into new international coordination and enforcement work with foreign regulators and labs.
Why It Matters
The bill creates a legal, federally supervised channel for price arbitrage that could reduce consumer costs while creating new operational and legal obligations for importers and foreign sellers. It alters manufacturer leverage over international pricing and supply practices and requires new data, testing, and international cooperation to manage safety and diversion risks.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill directs the Secretary of Health and Human Services to write final regulations — within one year — establishing when and how certain prescription drugs may be imported into the United States. It identifies categories of ‘‘qualifying prescription drugs’’ (including insulins, certain biologics and intravenously infused drugs, and drugs subject to REMS) and excludes controlled substances, inhaled anesthetics, and compounded drugs.
The regulations will set labeling expectations (including English labels), allow foreign labeling where it meets the Secretary’s standards, and make such imports non‑misbranded under section 502 when the labeling requirements are met.
To manage safety and supply integrity, the bill creates a certified foreign seller program. Foreign pharmacies and wholesalers located in specified countries must apply for certification, pay a fee set annually to cover program costs, and recertify every two years (or sooner on material change).
Certification criteria include licensing under the foreign country’s pharmacy laws, quality assurance programs (including blind testing), commitments to notify FDA and purchasers of recalls, grievance processes, and cooperation with FDA‑approved laboratory testing.Individuals may import a personal supply (up to a 90‑day supply) only when a certified foreign pharmacy dispenses the drug in response to a valid prescription issued after at least one in‑person medical evaluation by a U.S.‑licensed practitioner. Registered U.S. importers — defined as dispensers or wholesale distributors registered under section 503(e) — may import qualifying products for distribution, but must meet traceability and reporting requirements: biannual submissions to FDA that include manufacturer unique facility identifiers, transaction data (excluding certain confidential subparts), and prices paid.The FDA receives explicit tools to police the program: the authority to publish the certified seller list, approve laboratories for random chemical authenticity testing, suspend specific drugs or sellers immediately where there is a pattern of counterfeit/ recalled product or temporarily where risk is indicated, and enforce against discriminatory manufacturer conduct (such as differential pricing or supply denial intended to frustrate exports).
The bill also adds a criminal penalty (up to ten years or $250,000 fine) for internet actors who, with intent to defraud or reckless disregard for safety, sell adulterated or counterfeit drugs to U.S. consumers, and it requires periodic HHS and GAO reports analyzing safety, savings, and tracing outcomes.
The Five Things You Need to Know
The Secretary must establish implementing regulations within one year of enactment and publish a dedicated public list of certified foreign sellers with contact information.
Certified foreign sellers pay an annual certification fee (set to cover program costs), must meet quality assurance requirements, and will be recertified every two years or after material changes.
Individuals may import up to a 90‑day supply only if the drug is dispensed by a certified foreign pharmacy using a valid U.S. prescription issued after at least one in‑person medical evaluation.
The bill makes it unlawful for manufacturers to discriminate by charging higher prices to certified foreign sellers, to deny or restrict supply to certified sellers (except for drugs on the official shortage list), or to intentionally alter products to frustrate exports.
Importers must submit biannual reports to FDA containing manufacturer unique facility identifiers, transaction information, and the price paid; GAO must report on implementation 18 months after regulations take effect.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Formally names the statute the 'Affordable and Safe Prescription Drug Importation Act of 2025.' This is purely caption language and has no substantive legal effect beyond labeling the amendments.
Findings and sense of Congress
Sets out the legislative rationale: higher U.S. drug prices, existing FDA mutual recognition agreements, foreign manufacturing capacity, and current importation via enforcement discretion. The findings frame policy intent — both to expand legal importation and to emphasize required FDA oversight — and will matter later for statutory interpretation and agency rulemaking priorities.
Regulatory trigger and key definitions
Requires the Secretary to promulgate regulations within one year establishing the importation program. It defines core terms (certified foreign seller, importer, licensed foreign pharmacy, qualifying prescription drug, valid prescription) that determine who can participate, which products qualify, and what documentation is required. These definitions drive scope — for example, inclusion of certain biologics and exclusion of controlled substances — and create a baseline that will shape implementing rules and enforcement.
Certification, fees, and public list
Creates the certification pathway: foreign pharmacies and wholesalers in specified countries must be certified by FDA, pay a fee calibrated to program costs, and meet explicit operational criteria — licensing, QA programs (including blind testing), recall notification, grievance mechanisms, and restrictions on selling products not lawfully sold in their home market. The Secretary posts a dedicated website with certified seller contact information. Recertification every two years and material‑change triggers give FDA recurring touchpoints for oversight.
Geographic expansion, labeling, and laboratory testing
Authorizes importation initially from Canada, the UK, EU member states, and Switzerland, and gives FDA the authority to add other countries after reviewing safety data and program reports; the statute sets substantive criteria for admitting new countries (standards for approval, manufacturing practices, adverse event reporting, recalls). Approved imports meeting labeling requirements are deemed not misbranded; FDA may also approve laboratories to perform random chemical authenticity testing of products sold by certified foreign sellers.
Manufacturer restrictions, suspensions, reporting, and REMS coverage
Bars manufacturers from discriminatory pricing or supply restrictions aimed at impeding imports (with a narrow shortage exception) and from intentionally differentiating products to prevent exports. FDA can immediately suspend imports for patterns of counterfeit/recalled products or temporarily suspend pending investigation. Importers must submit biannual reports (including manufacturer facility identifiers and prices paid) that FDA will retain. The statute also requires importers to comply with REMS where applicable, and imposes supply chain requirements limiting purchases to registered manufacturers or certified sellers, with a path for MOUs/cooperative agreements to enable purchases from foreign sellers not registered under section 510.
New criminal penalty for online bad actors and reporting requirements
Adds a criminal provision penalizing operators of internet sites that sell adulterated or counterfeit drugs to U.S. individuals with intent to defraud or with reckless disregard for safety (up to 10 years imprisonment or $250,000 fine). It also requires HHS to report to Congress and the public one year after regulations are final and every two years thereafter, and requires a GAO review 18 months after regulations take effect analyzing safety, cost savings, and tracing outcomes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Cash‑paying and high cost‑sharing patients: expands lawful access to lower‑priced versions of many prescription drugs and allows limited personal imports (up to 90 days) dispensed by certified foreign pharmacies, which can immediately reduce out‑of‑pocket costs for certain individuals.
- U.S. pharmacies and registered wholesale distributors that elect to become importers: gain a new supply option and potential margin or cost savings if they manage compliance and traceability requirements effectively.
- Certified foreign pharmacies and wholesale distributors in participating countries: obtain regulated access to the U.S. retail market, expanding sales opportunities if they meet certification and quality requirements.
- Self‑insured employers and health plans: may realize lower drug spend if plan sponsors or providers utilize imported drugs in benefit designs or as part of patient assistance programs, reducing short‑term pharmacy costs.
Who Bears the Cost
- Prescription drug manufacturers: face restrictions on pricing and supply strategies, potential loss of foreign market segmentation, and legal exposure under the statute’s anti‑discrimination provisions; they may incur costs if forced to change distribution or labeling practices.
- FDA / HHS and federal laboratories: take on significant new regulatory, inspection, testing, and oversight responsibilities — although certification fees are intended to defray program costs, initial implementation and ongoing international coordination will demand staff, systems, and legal resources.
- U.S. importers and pharmacies: must absorb compliance costs — registration, quality assurance, participation in testing programs, recordkeeping, biannual reporting, and potential interruptions if FDA suspends imports — and will face operational complexity integrating foreign labeling and tracing data.
- Certified foreign sellers: must invest to meet certification criteria (quality assurance programs, licensing verification, recall processes) and face reputational and business risk if FDA suspends certification or enforces against noncompliance.
Key Issues
The Core Tension
The bill’s central dilemma is trade‑offs between immediate consumer access to lower‑priced medicines and the integrity of U.S. regulatory and supply systems: enabling cross‑border imports can reduce out‑of‑pocket costs but requires ceding some traditional FDA control over manufacture and distribution to foreign systems, while imposing new administrative and compliance burdens that may shrink supplier willingness to sell into importing markets and shift risks to importers and the federal agency charged with oversight.
The bill marshals a complex set of compliance and enforcement tools, but its success depends on operational details the statute leaves to rulemaking. Key unanswered implementation questions include how FDA will verify foreign QA programs at scale (especially for online pharmacies), the laboratory capacity and standards for random chemical authenticity testing, and how FDA will reconcile differing product formulations or excipient profiles that are lawful abroad but differ from FDA‑approved U.S. products.
The statute permits MOUs with foreign regulators to manage supply chain verifications, but reaching meaningful cooperative agreements — particularly on inspection access, recall coordination, and data sharing — is legally and diplomatically complicated.
Market responses also pose practical tensions. Manufacturers may react by tightening foreign supply, changing formulations tied to specific markets, or altering pricing outside the program, which could blunt consumer savings or shift costs elsewhere.
The biannual reporting requirement creates transparency but raises questions about proprietary commercial data, international data security, and FDA’s capacity to analyze price and transaction data quickly enough to detect diversion or transshipment. Finally, applying REMS and other risk‑mitigation tools to imported products raises liability and operational questions for importers and prescribers that the rulemaking must resolve.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.